TOP > 外国特許検索 > METHOD FOR PRODUCING OSTEOBLAST CLUSTER USING IPS CELLS

METHOD FOR PRODUCING OSTEOBLAST CLUSTER USING IPS CELLS

Foreign code F200010231
File No. (S2019-0268-N0)
Posted date 2020年10月29日
Country 世界知的所有権機関(WIPO)
International application number 2020JP007876
International publication number WO2020175592
Date of international filing 令和2年2月26日(2020.2.26)
Date of international publication 令和2年9月3日(2020.9.3)
Priority data
  • 特願2019-033277 (2019.2.26) JP
Title METHOD FOR PRODUCING OSTEOBLAST CLUSTER USING IPS CELLS
Abstract A method for producing an osteoblast cluster from iPS cells, said method comprising: (1) a step for inducing the formation of embryoid bodies by non-adhesively culturing undifferentiated iPS cells; (2) a step for inducing the differentiation of the iPS cells into mesodermal cells by non-adhesively culturing the embryoid bodies of the iPS cells obtained in step (1); and (3) a step for inducing the differentiation into osteoblasts by non-adhesively culturing the mesodermal cells of the iPS cells obtained in step (2), wherein the aforesaid steps (1) and (2) are carried out using a culture container which is provided with a bottom face and a circular side wall standing from the bottom face and in which a plurality of concave portions are formed in the bottom face in such a manner as to be independent from each other.
Outline of related art and contending technology Background Art
The demand for artificial bone/bone prosthetic materials for supplementing bone tumor extraction, crushed bone fracture, bone defects associated with fixation of rheumatoid arthritis, bone defects lost due to maxilla resorption, etc., has been very increasing.
At present, non-resorbable materials such as hydroxyapatite and resorbable materials such as / S-3-th calcium phosphate, which are currently used as artificial bone/bone prosthetic materials in clinical use, have problems such as lack of osteoinductive properties compared to autologous bone, and thus have not always good prognosis of surgical procedures. A hybrid artificial bone obtained by combining a human e bone desired to be developed and promoted as a next generation type with a growth factor protein such as BMP (B o n e Mo r p h o g e n e t i c P r o t e i n) is also provided. Since the bone prosthetic material has no "extracellular matrix" important for bone tissue regeneration, sufficient bone regeneration effect cannot be obtained.
Under such circumstances, the inventors succeed in producing a bone regeneration agent using stem cells as a raw material, comprising inactivated cell clusters, wherein the inactivated cell clusters comprise at least calcified products and extracellular matrix.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • TOHOKU UNIVERSITY
  • Inventor
  • EGUSA, Hiroshi
  • OKAWA, Hiroko
  • HORIE, Naohiro
  • KONDO, Takeru
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までご連絡ください。

PAGE TOP

close
close
close
close
close
close